KU-55933 (ATM Kinase Inhibitor)

For research use only.

Catalog No.S1092

201 publications

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

CAS No. 587871-26-9

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR. KU‑55933 (ATM Kinase Inhibitor) inhibits the activation of autophagy‑initiating kinase ULK1 and results in a significant decrease of autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
USD 947 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's KU-55933 (ATM Kinase Inhibitor) has been cited by 201 publications

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR. KU‑55933 (ATM Kinase Inhibitor) inhibits the activation of autophagy‑initiating kinase ULK1 and results in a significant decrease of autophagy.
Targets
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 NWnQRnplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPaRlBiUUN3ME2zMlI4OzV{IN88US=> M3PycXNCVkeHUh?=
HuO-3N1 NVrBfHVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vtUGlEPTB;ND6xO|E1OiEQvF2= NIjWc|NUSU6JRWK=
LAMA-84 NWjXUJZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXJTWM2OD12LkW4OFY2KM7:TR?= MmiwV2FPT0WU
CAL-72 MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv6TWM2OD13LkS4NFg1KM7:TR?= NUjI[It5W0GQR1XS
LoVo NXrHcHE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTZwOUOyN|kh|ryP MmTrV2FPT0WU
HH MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFix[|JKSzVyPUiuNlc3PzFizszN NHzFZnVUSU6JRWK=
SK-MEL-3 MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPyepMyUUN3ME24MlI5PTd3IN88US=> M1f3UHNCVkeHUh?=
KM12 NVOyNIhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTlwMkGxOFIh|ryP M3n5TnNCVkeHUh?=
NCI-H1437 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPnTWM2OD17LkiwPVch|ryP MnrVV2FPT0WU
NCI-H1838 NWHodZdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFzLkG4OlUh|ryP NYCwVlh5W0GQR1XS
J-RT3-T3-5 M{n6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS0SJlzUUN3ME2xNU4zPDF5IN88US=> NGLYPIJUSU6JRWK=
GOTO NWDU[VV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6xOFJKSzVyPUGxMlY6QTZizszN M1G4SnNCVkeHUh?=
LB2241-RCC NY\sb5ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL0Z2V1UUN3ME2xNU44OTh4IN88US=> MVPTRW5ITVJ?
ES7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPTTWM2OD1zMT63PFgh|ryP M3PUeXNCVkeHUh?=
KP-N-YS MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PNRmlEPTB;MUKuOlM2PCEQvF2= NXTBNotsW0GQR1XS
CAL-12T MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKwVFlKSzVyPUGzMlYyPyEQvF2= NULsVGh3W0GQR1XS
COLO-684 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PkWWlEPTB;MUSuNVU3QSEQvF2= MnLVV2FPT0WU
DOK NUL4U2R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rH[GlEPTB;MUWuN|MzQSEQvF2= NUPUcFRLW0GQR1XS
Hs-578-T MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3KTJdKSzVyPUG1MlQyQDJizszN MoDiV2FPT0WU
D-423MG NWPQbmxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nqdGlEPTB;MUWuOVI{PiEQvF2= MYrTRW5ITVJ?
DBTRG-05MG M1f3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu2OFl5UUN3ME2xOU43OTFzIN88US=> MYnTRW5ITVJ?
VM-CUB-1 MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf6WZhZUUN3ME2xOU46QDR7IN88US=> MmK2V2FPT0WU
KG-1 MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTnS4xlUUN3ME2xOk4xQTl4IN88US=> MXPTRW5ITVJ?
8305C NWXldpBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC0cHlIUUN3ME2xOk4yQDh7IN88US=> NX75TJFpW0GQR1XS
HuH-7 NEHlZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHhfXNKSzVyPUG2MlI3PzRizszN NVPqT4hHW0GQR1XS
LXF-289 MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvJUVdKSzVyPUG2MlI4PDdizszN NIPUZ2ZUSU6JRWK=
NCI-H1793 NUXxNnZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF4LkS3NVIh|ryP MX\TRW5ITVJ?
ChaGo-K-1 MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF4Lk[1Olgh|ryP M4HzOHNCVkeHUh?=
GCIY MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnuwTWM2OD1zNj63PVA2KM7:TR?= M3j5[XNCVkeHUh?=
SK-MEL-28 NET5[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\UXmlEPTB;MUeuNFQ4PSEQvF2= NG\qWG1USU6JRWK=
NCI-SNU-1 NFHhUXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF5LkGyOlkh|ryP NHrLWolUSU6JRWK=
CTB-1 M2jpd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF5LkKyOVkh|ryP NEH2TmxUSU6JRWK=
NCI-H82 NUm0dnFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT0OGMyUUN3ME2xO{41PTd|IN88US=> NWfvO|gxW0GQR1XS
HCC2998 Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XSVmlEPTB;MUeuOlc{OyEQvF2= MVHTRW5ITVJ?
NCI-H2030 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHRTWM2OD1zOD6xPVk4KM7:TR?= MnjYV2FPT0WU
HuP-T3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe2V4ZGUUN3ME2xPE42QDh6IN88US=> M3HWUXNCVkeHUh?=
697 Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonyTWM2OD1zOT6wNlAyKM7:TR?= MkLyV2FPT0WU
MLMA M3XJXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz6[XBvUUN3ME2xPU4xPTV5IN88US=> M1T3XHNCVkeHUh?=
HCC70 M3W5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mli5TWM2OD1zOT60PFkh|ryP M4PGU3NCVkeHUh?=
A704 MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDyTWM2OD1zOT64N|A2KM7:TR?= M3fVc3NCVkeHUh?=
D-283MED MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJyLkWzN|kh|ryP MYXTRW5ITVJ?
U031 NVzzPIw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3uTWM2OD1{MT6xOFg6KM7:TR?= MX3TRW5ITVJ?
HSC-3 M2PGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnUPJBKSzVyPUKxMlE5OzVizszN MmP3V2FPT0WU
JVM-3 NFP6d5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn5XGZmUUN3ME2yNk42ODZizszN MmrVV2FPT0WU
Mewo M2Li[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X6RmlEPTB;MkKuOVA4OyEQvF2= NH7NTmtUSU6JRWK=
YH-13 MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jZdGlEPTB;MkKuOVEzOyEQvF2= NHrZdZFUSU6JRWK=
LB1047-RCC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC2TWM2OD1{Mj61PFc6KM7:TR?= MXnTRW5ITVJ?
HCC2157 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv2fVdKSzVyPUKyMlgxPTRizszN Moe2V2FPT0WU
SNU-449 NVPKXZlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJ{Lki3OFgh|ryP NUS2WW0{W0GQR1XS
Ramos-2G6-4C10 M4nlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\IdmlEPTB;MkKuPVYh|ryP MmPJV2FPT0WU
CHL-1 NGPDXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfKW4lKSzVyPUKzMlczQTJizszN MX7TRW5ITVJ?
SK-MEL-30 M{DR[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJ2LkS2OlIh|ryP Mn[1V2FPT0WU
PANC-08-13 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PROWlEPTB;MkWuNFk{QCEQvF2= MXnTRW5ITVJ?
QIMR-WIL MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJ3LkG4OVgh|ryP NWTNV3lnW0GQR1XS
BFTC-905 NWm5[YNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHofIpKSzVyPUK1MlU6PDRizszN NUWye|RwW0GQR1XS
GI-1 MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P3UGlEPTB;MkWuO|A2PSEQvF2= MlrVV2FPT0WU
MDA-MB-415 NXTwdGVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJ4LkWwN|Mh|ryP NUOyT|EzW0GQR1XS
GT3TKB NY[xVmN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXiNJhQUUN3ME2yOk42OzR{IN88US=> M1v1XHNCVkeHUh?=
DEL M4TjfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJ4LkizOVYh|ryP MWrTRW5ITVJ?
KOSC-2 NVPCOphlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvDb4RKSzVyPUK2MlkxPzVizszN NI[4dZVUSU6JRWK=
RVH-421 NVjHcFBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf0TWM2OD1{Nz6yPVIyKM7:TR?= MUPTRW5ITVJ?
EW-13 MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT2O2U3UUN3ME2yO{41OzB6IN88US=> MlHDV2FPT0WU
639-V MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljITWM2OD1{Nz61NVE6KM7:TR?= MonGV2FPT0WU
A2780 NWLFZ4hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfFcWxKSzVyPUK3MlY1OSEQvF2= NYfSZol5W0GQR1XS
SW982 MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7pcY5KSzVyPUK3MlkxPTJizszN MlexV2FPT0WU
SW1710 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLYSXBKSzVyPUK4MlA6QDFizszN MXPTRW5ITVJ?
HCC1569 NWLJfllIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX1TWM2OD1{OD60PFk4KM7:TR?= NYf3VJhMW0GQR1XS
MV-4-11 NILD[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJ6LkW3N|Uh|ryP M2iyRnNCVkeHUh?=
BHT-101 NEXDSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTDWWVKSzVyPUK4MlY2PzJizszN NXfqWIs{W0GQR1XS
Ca9-22 NVHkelZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7PTWM2OD1{OD63NVQh|ryP NFXuVY5USU6JRWK=
HAL-01 NF3kVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S4VmlEPTB;MkiuO|YyPSEQvF2= NEnaWVVUSU6JRWK=
D-263MG M2\tbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33uS2lEPTB;MkmuN|Q1KM7:TR?= Ml\JV2FPT0WU
NEC8 MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHUTWM2OD1{OT61OVQ5KM7:TR?= NGXyd2RUSU6JRWK=
EKVX NX;ycnI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTFVFRKSzVyPUOxMlU5PDdizszN NGHQb|JUSU6JRWK=
EM-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTNzLk[zNFQh|ryP M4DldXNCVkeHUh?=
MFM-223 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTNzLkiwPVgh|ryP MnznV2FPT0WU
SK-PN-DW MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HNSWlEPTB;M{KuNVQxPiEQvF2= NV3xbINoW0GQR1XS
HuO9 MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHWbG9KSzVyPUOyMlUzQDJizszN NIjZ[4hUSU6JRWK=
MHH-PREB-1 M{DFNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTN{Lk[yN|Qh|ryP NYC1WHZ1W0GQR1XS
OVCAR-4 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHETWM2OD1|Mj64N|Y{KM7:TR?= MV;TRW5ITVJ?
NCI-H1648 MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTN{Lki2OVEh|ryP MnSxV2FPT0WU
MKN1 M3LaUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnVbXNKSzVyPUO0MlEyODFizszN NIHaVYlUSU6JRWK=
KYSE-450 NX71[YdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M136Z2lEPTB;M{SuOlQ1PCEQvF2= MlThV2FPT0WU
ES8 NFvLd4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETtWm5KSzVyPUO0Mlg6PzVizszN NWnnZnl4W0GQR1XS
MS-1 MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTN2Lkm1OVQh|ryP M2DJVXNCVkeHUh?=
HOP-92 MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXIR4xVUUN3ME2zOU46Ojd5IN88US=> M2HsRnNCVkeHUh?=
SKG-IIIa NXP1[lR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm3[pBkUUN3ME2zOk4zPTZzIN88US=> M3i1cHNCVkeHUh?=
TE-11 MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlKzTWM2OD1|Nj61NlQ{KM7:TR?= M4W4SXNCVkeHUh?=
SK-NEP-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzB[JlKSzVyPUO3MlY4PDRizszN Mn;VV2FPT0WU
DB M2DRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13HemlEPTB;M{euPVE5PSEQvF2= NEDkb|BUSU6JRWK=
IA-LM M4XvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL1UplNUUN3ME2zPE4xOjN7IN88US=> MYTTRW5ITVJ?
COLO-829 NYXF[Yk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTN6LkSxOVkh|ryP MkTsV2FPT0WU
TGBC11TKB M4rHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIGwNmZKSzVyPUO5MlE1ODhizszN M3y0O3NCVkeHUh?=
CAL-51 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moe1TWM2OD12MD6wOlEzKM7:TR?= MofNV2FPT0WU
NCI-H2228 NF7DcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7qTWM2OD12MD6zOlYzKM7:TR?= M{HnN3NCVkeHUh?=
C32 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTRyLkSwNlQh|ryP NG\VSpFUSU6JRWK=
KU-19-19 M{XN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXYbYhVUUN3ME20NE44Pjh|IN88US=> NXv4OYRlW0GQR1XS
KNS-62 M3rqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPYS2hKSzVyPUSwMlg{QDFizszN MXPTRW5ITVJ?
FADU Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LUZ2lEPTB;NEGuNlUxOiEQvF2= NYjofIt6W0GQR1XS
CAL-33 NFvXenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTR{Lk[3OFkh|ryP MXnTRW5ITVJ?
CHP-134 NInqNFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTR{Lki0PVYh|ryP NVSxcGtvW0GQR1XS
HDLM-2 NVPRcIFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnlTWM2OD12Mj65NFg1KM7:TR?= NXHVdFY4W0GQR1XS
NBsusSR NV\we|huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LrVmlEPTB;NEOuNFczPSEQvF2= NYnSdGZ2W0GQR1XS
SW954 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnU[WNyUUN3ME20N{4yODV|IN88US=> M4LtTnNCVkeHUh?=
HCC1806 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jINmlEPTB;NEOuOFEyKM7:TR?= Mn\kV2FPT0WU
VMRC-RCZ NV2zRnZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTR|LkS1PFYh|ryP MnfRV2FPT0WU
A549 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHRZpRKSzVyPUSzMlk{OSEQvF2= NX;mS|Z3W0GQR1XS
NKM-1 MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\F[HRDUUN3ME20N{46PTV6IN88US=> MWDTRW5ITVJ?
DMS-273 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHxfHVKSzVyPUS0Mlc2PjdizszN NUKxSJdlW0GQR1XS
TYK-nu MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrsTWM2OD12NT6xNlM1KM7:TR?= Mom0V2FPT0WU
KALS-1 Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTR3LkG0OkDPxE1? M1vid3NCVkeHUh?=
A101D NFfyWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojTTWM2OD12NT60OFU3KM7:TR?= MlvxV2FPT0WU
G-361 MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXaWWxsUUN3ME20Ok4zOTN6IN88US=> NH;FSpRUSU6JRWK=
KARPAS-299 NUju[HFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTR4LkO1NVYh|ryP NH\ISGNUSU6JRWK=
RS4-11 MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fJOmlEPTB;NE[uOVQzKM7:TR?= MX7TRW5ITVJ?
HT-1376 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rGPWlEPTB;NE[uO|QzPiEQvF2= Mn;FV2FPT0WU
SK-N-AS NUHVVopMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTR4Lke4NlIh|ryP NXjTRZhCW0GQR1XS
MG-63 M3nsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrydYFvUUN3ME20Ok46ODN4IN88US=> MYPTRW5ITVJ?
EPLC-272H Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLKeVkxUUN3ME20Ok46PTB|IN88US=> MWfTRW5ITVJ?
BALL-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml25TWM2OD12Nz64N|Ih|ryP NIrMemJUSU6JRWK=
LCLC-97TM1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTR6LkKwNkDPxE1? NHm5VWtUSU6JRWK=
HO-1-N-1 M1\oNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrEeGtKSzVyPUS4Mlk3PzZizszN M1zDZnNCVkeHUh?=
MFE-280 MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFKxXYlKSzVyPUS5MlQ3OTdizszN MlnuV2FPT0WU
NCI-H526 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTmOHNbUUN3ME20PU45OTZ|IN88US=> NVjhO2d6W0GQR1XS
D-566MG MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTR7LkmwPVYh|ryP NGjUOZBUSU6JRWK=
BB30-HNC M2\3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLaTWM2OD12OT65OFk5KM7:TR?= NVTGSHloW0GQR1XS
SK-N-DZ NFr2VYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfRTWM2OD13MD6wOFgyKM7:TR?= MUTTRW5ITVJ?
HepG2  NVPjeI9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXNUmIyOMLizszN MnfoNlQhcA>? M3fIU4Jtd2OtczDTR{1KUUl|LXnu[JVk\WRiUzDwbIF{\SCjcoLld5Q> NVzERYZDOjV3MkexNlM>
HepG2  NFLadHlHfW6ldHnvckBCe3OjeR?= M{jRUVExyqEQvF2= MojQNlQhcA>? NVnoO5VDe3WycILld5NmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wczDv[kBCXE1ib36gV4VzOTl6MTygR4hsOSCxbjDT[ZI{PDVuIFPob|Ihd25iVHjyOlgtKGGwZDDD[IszKG:wIGT5dlE2KGmwZIXj[YQh[nliU1OtTWlKOw>? NIryNlUzPTV{N{GyNy=>
KATO III  Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHBNk42NzVxNz61JO69VQ>? M2jFSGROW09? NWXJRnZO\W6qYX7j[ZMhfGinIITvfIlkcXS7IH;mJI9t[XCjcnni MmCxNlQ5PDF5MUi=
hTCEpi M13XeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPQNVAh|ryP NF7OV2VFVVOR NIrDb3dxemW4ZX70d{B1cGViY4n0c5BifGirYzDl[oZm[3Rib3[gTHNXNTF? NUWxOJBMOjR|N{C4N|U>
MCF10A MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXCNVAh|ryP NX7xbFBFOjRiaB?= NVfSdJY1TE2VTx?= NFvrN4Fxd3SnboTpZZRmeyC2aHWgZ5l1d3SxeHnjbZR6KG:oIFfB NV7a[I1kOjRzNUC1PVU>
HL-60  MY\GeY5kfGmxbjDBd5NigQ>? NWnDSpNyOTBizszN NV;5OY9xOC53IHi= MWXEUXNQ NHThbnJz\WS3Y3XzJJBpd3OyaH;yfYxifGmxbjDv[kBEcGt{wrC= NH7BT5IzOzl|NESxNS=>
MCF-7 NVTtfIpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrQNnJiOS1zMEFOwG0> NV;mbYN4OjRiaB?= NEj1WolHSlN? NF\I[JJqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w NYDiUIxTOjNzOEWzOFc>
HeLa  MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPnNU0yODEQvF2= NYrIdHJ6OjRiaB?= MoTnSmJU MU\pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v NFOzNGszOzF6NUO0Oy=>
SH-SY5Y MYfGeY5kfGmxbjDBd5NigQ>? M3\mS|ExyqEQvF5CpC=> MmniNlQhcA>? M2\w[IlvcGmkaYTzJINtcW:zdXnuc4wucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YheDV| MX2yNlYzPzJ7NB?=
IMR-32 NXjucIpETnWwY4Tpc44hSXO|YYm= MYqxNOKh|ryPwrC= MYGyOEBp MkjhbY5pcWKrdIOgZ4xqd3G3aX7vcE1qdmS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBxPTN? NYXjZ4tLOjJ4MkeyPVQ>
A549 M1rSWWZ2dmO2aX;uJGF{e2G7 M4nIV|ExyqEQvF5CpC=> NXTEXGkzOSCq NWjsbGI5e3WycILld5NmeyCQYX7vMWNwNWmwZIXj[YQheDV|IHHjZ5VufWyjdHnvci=> NHHKSYIzOjV3OUOyNS=>
T47D  MVTGeY5kfGmxbjDBd5NigQ>? MV:yNOKhdU1? M3rxdlI1KGh? M2P2U2ROW09? MYXwdoV3\W62czDJVk1qdmS3Y3XkJIRm\3KjZHH0bY9vKG:oIFpOvmLPuQ>? MmTRNlEyPDR6MEW=
A29 MEF M2HveGZ2dmO2aX;uJGF{e2G7 MYixNOKh|ryPwrC= NH65XYwycA>? MVvicI9kc3QEoITo[UBxcG:|cHjvdplt[XSrb36gc4YhSWu2IHH0JHNmejR5M9Mg MkLwNlAxPTN5OEG=
MDA-MB-453  MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1r6UlUuPDBizszN Mle2O|IhcA>? MmfMTWM2OCCxZjCxNEDPxE1? MX2yNFA2Ozd6MR?=
PC-3 NYq5WXFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DmdVUuPDBizszN NF6yb3o4OiCq M{fDU2lEPTBib3[gNVAh|ryP NWLCWnNEOjByNUO3PFE>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT(Ser473) / p-AKT(Thr308); 

PubMed: 22739265     


Cells were serum-starved for 6 h and treated with KU-55933 (10 µmol/L) for 1 h before treatment with insulin (100 nmol/L) for 45 min. Cells were lysed, and cell lysates were subjected to SDS-PAGE and Western blotting for the detection of phospho-Akt at Se䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖

PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; 

PubMed: 22739265     


ATM inhibition by KU-55933 induces apoptosis in differentiated but not undifferentiated SH-SY5Y cells. Cells were starved for 6 h in serum-free medium. KU-55933 (10 µmol/L) was added 1 h before insulin (100 nmol/L) treatment. After 3 h of insulin stimulat䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤

ATM-S1981 / ATM / p-p53(S15) / p53 ; 

PubMed: 20639198     


Antioxidant and ATM inhibitors blocked phosphorylation of ATM-S1981, Akt-S473, and p53-S15 as stimulated by H2O2 exposure. Cells were treated with 100 μm H2O2 for 30 min in the absence or presence of KU-55933. Whole cell lysates were subjected to Western 䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖

p21 / p27 / p53 ; 

PubMed: 20177072     


HMGE cells were incubated for the indicated times with 1 μm KU-55933 or DMSO. Total protein extracts were analyzed by Western blotting for p21WAF1/CIP1, p27KIP1, p53, or β-actin.

22739265 20639198 20177072
Immunofluorescence
p-S824 KAP1 / ZEBRA ; 

PubMed: 28249048     


HH514-16 cells were treated with NaB (upper panel) or NaB plus KU-55933 (1μM; middle panel) or NaB plus Torin1 (0.5μM; lower panel) for 24 hours and stained with anti-phospho KAP1 (S824) plus anti-ZEBRA antibodies and visualized at 1000X magnification.

28249048
In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:

[1]

- Collapse

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:

[1]

- Collapse
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing.
3.95 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2

CAS No. 587871-26-9
Storage powder
in solvent
Synonyms N/A
Smiles C1COCCN1C2=CC(=O)C=C(O2)C3=C4C(=CC=C3)SC5=CC=CC=C5S4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID